RecruitingGastroesophageal Adenocarcinoma

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).

Sponsor: University of California, Irvine

You may qualify if…

✓ Patients must have histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEA). Other GE histologies which are treated per NCCN guidelines for neoadjuvant treatment are eligible.
✓ Must have Stage IB, II or Stage III GEA eligible for (neo)adjuvant doublet or triplet chemotherapy for up to 6 months.
✓ Age ≥ 18 years Because the safety or efficacy of neoadjuvant chemotherapy for LGEA has not been tested or established for patients \<18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable.
✓ Performance status: ECOG performance status ≤2
✓ Life expectancy of greater than 6 months
✓ Adequate organ and marrow function as defined below:
✓ 1. hemoglobin ≥ 7g/dL
✓ 2. absolute neutrophil count ≥ 1,500/mcL

You may not qualify if…

✕ Patients may not be receiving any other investigational agents.
✕ Patients with known distant metastases from GEA.
✕ History of allergic reactions attributed to agents used in study.
✕ Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
✕ History of another primary cancer which requires active treatment or is expected to require treatment within 12 months after enrollment.
✕ Inability to comply with study and follow-up procedures as judged by the Investigator.
✕ Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
✕ Patients with prior organ/bone marrow/non-autologous stem cell transplants

Where it's recruiting

California

Orange

Source: ClinicalTrials.gov · NCT05733689 · last updated 2026-03-10